Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions

NCT01597050 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Erythematosus, Discoid
Lupus Erythematosus, Systemic

Interventions

DRUG: R932333
DRUG: Placebo

Sponsor

Rigel Pharmaceuticals